Search research articles
Contact Us
Filters
Showing results (11-20 of 106) with videos related to
Page
of 11
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 10, 2022
How Much Does the US Public Value Equity in Health? A Systematic Review
Sara Khor, Zizi A Elsisi, Josh J Carlson
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
October 28, 2015
A Framework for Prioritizing Research Investments in Precision Medicine
Anirban Basu, Josh J Carlson, David L Veenstra
Journal of Managed Care & Specialty Pharmacy
|
July 28, 2020
Economic Burden of Metastatic Ovarian Cancer in a Commercially Insured Population: A Retrospective Cohort Analysis
Lauren Chin, Ryan N Hansen, Josh J Carlson
Journal of Managed Care & Specialty Pharmacy
|
July 31, 2023
Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis
Joseph Yang, Natalie Boytsov, Josh J Carlson, et al.
Pharmacoeconomics
|
March 6, 2021
Authors' Reply to Comment on "Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome"
Edward E Neuberger, Josh J Carlson, David L Veenstra
Journal of Geriatric Oncology
|
April 19, 2023
Quantifying the value of older adult-specific clinical trials: Post-lumpectomy irradiation among older adults with early-stage breast cancer
Woojung Lee, Josh J Carlson, Anirban Basu, et al.
Pharmacoeconomics
|
March 1, 2018
Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer
Josh J Carlson, Kangho Suh, Panos Orfanos, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
May 15, 2018
Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim
Simrun Grewal, Scott Ramsey, Sanjeev Balu, et al.
Journal of Managed Care Pharmacy : JMCP
|
October 7, 2009
Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals
Josh J Carlson, Louis P Garrison, Sean D Sullivan
Drugs
|
May 20, 2008
Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer
Josh J Carlson, David L Veenstra, Scott D Ramsey
Page
of 11
Search research articles
Search
Showing results (11-20 of 106) with videos related to
Sort By:
Page
of 11
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 10, 2022
How Much Does the US Public Value Equity in Health? A Systematic Review
Sara Khor, Zizi A Elsisi, Josh J Carlson
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
October 28, 2015
A Framework for Prioritizing Research Investments in Precision Medicine
Anirban Basu, Josh J Carlson, David L Veenstra
Journal of Managed Care & Specialty Pharmacy
|
July 28, 2020
Economic Burden of Metastatic Ovarian Cancer in a Commercially Insured Population: A Retrospective Cohort Analysis
Lauren Chin, Ryan N Hansen, Josh J Carlson
Journal of Managed Care & Specialty Pharmacy
|
July 31, 2023
Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis
Joseph Yang, Natalie Boytsov, Josh J Carlson, et al.
Pharmacoeconomics
|
March 6, 2021
Authors' Reply to Comment on "Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome"
Edward E Neuberger, Josh J Carlson, David L Veenstra
Journal of Geriatric Oncology
|
April 19, 2023
Quantifying the value of older adult-specific clinical trials: Post-lumpectomy irradiation among older adults with early-stage breast cancer
Woojung Lee, Josh J Carlson, Anirban Basu, et al.
Pharmacoeconomics
|
March 1, 2018
Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer
Josh J Carlson, Kangho Suh, Panos Orfanos, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
May 15, 2018
Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim
Simrun Grewal, Scott Ramsey, Sanjeev Balu, et al.
Journal of Managed Care Pharmacy : JMCP
|
October 7, 2009
Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals
Josh J Carlson, Louis P Garrison, Sean D Sullivan
Drugs
|
May 20, 2008
Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer
Josh J Carlson, David L Veenstra, Scott D Ramsey
Page
of 11